Eckert & Ziegler: Affiliates Receive Additional NIAID Funding To Advance Pharmaceutical Development

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Keyword (s): Contract

Eckert & Ziegler: Affiliates Receive Additional NIAID Funding To Advance Pharmaceutical Development

08.06.2021 / 09:30
The issuer is solely responsible for the content of this advertisement.

Berlin, June 8, 2021 – Myelo Therapeutics GmbH, a subsidiary of Eckert & Ziegler (ISIN DE0005659700, TecDAX) focused on the development of medical countermeasures (MCMs) and therapies for supportive cancer care, announced that The US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has extended its contract to advance development of the new chemical entity Myelo001. The second year extension of the three-year contract provides an additional $ 2 million for Myelo Therapeutics to develop Myelo001 clinically as an MCM oral formulation for the treatment of acute hematopoietic radiation syndrome (H-ARS). The total contract, initially awarded in April 2020, is valued at $ 6.2 million over three years if all options are exercised.

The additional funds will advance the development of Myelo001 as an H-ARS monotherapy and in polypharmacy regimens in laboratory models ranging from rodents to larger animals towards a new investigative drug application (IND) with the United States Food and Drug Administration (FDA). The candidate MCM development program is funded in whole or in part by the Radiation and Nuclear Countermeasures Program (RNCP), NIAID, which is part of the National Institutes of Health (NIH), of the Department of Health and Human Services (HHS), under Contract No. 75N93020C00005. Only a small number of companies are funded by the RNCP, based on a very competitive application process.

About acute radiation syndrome
RAS, also known as radiotoxicity or radiation sickness, is an acute illness that manifests itself after large parts of the body are exposed to high levels of radiation, such as those that might occur during a radiological incident or nuclear. The main manifestation of RAS is the depletion of hematopoietic stem and progenitor cells, which is one of the main causes of death. The US government is encouraging the development of new drugs to treat bodily injuries resulting from ARS.

About Myelo Therapeutics
Myelo Therapeutics is a pharmaceutical company based in Berlin, Germany that develops innovative treatments in areas where unmet medical needs are high, such as chemotherapy-induced myelosuppression (ICD), radiation-induced myelosuppression (RIM ) and ARS. Myelo’s lead candidate, Myelo001 is an adjuvant, clinical-stage cancer therapy for the treatment of myelosuppression induced by chemotherapy and radiation therapy. It comes as an oral tablet and is stable at room temperature for at least three years. Preclinical and clinical studies have shown that Myelo001 has both prophylactic and therapeutic efficacy in reducing hematopoietic symptoms caused by radiation therapy and chemotherapy. Eckert & Ziegler is one of the main shareholders of Myelo and has financed a substantial part of the development activities of Myelo001.

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG, with its 800 employees, is a leading specialist in isotope-related components in nuclear medicine and radiotherapy. The company offers a wide range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Help save lives.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Phone. : +49 (0) 30/94 10 84-138, [email protected],

08.06.2021 Distribution of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this advertisement.

DGAP’s distribution services include regulatory announcements, financial / corporate news, and press releases.
Archives on

Source link

About Catherine Sherrill

Check Also

Hedge funds in standby mode

Last year, we predicted the onset of the first US recession since 2009 and we …

Leave a Reply

Your email address will not be published. Required fields are marked *